ZA201109332B - Treatment of heart failure with normal ejection fraction - Google Patents

Treatment of heart failure with normal ejection fraction

Info

Publication number
ZA201109332B
ZA201109332B ZA2011/09332A ZA201109332A ZA201109332B ZA 201109332 B ZA201109332 B ZA 201109332B ZA 2011/09332 A ZA2011/09332 A ZA 2011/09332A ZA 201109332 A ZA201109332 A ZA 201109332A ZA 201109332 B ZA201109332 B ZA 201109332B
Authority
ZA
South Africa
Prior art keywords
treatment
heart failure
ejection fraction
normal ejection
normal
Prior art date
Application number
ZA2011/09332A
Other languages
English (en)
Inventor
Houman Ashrafian
Michael Paul Frenneaux
Original Assignee
Heart Metabolics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Heart Metabolics Ltd filed Critical Heart Metabolics Ltd
Publication of ZA201109332B publication Critical patent/ZA201109332B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4458—Non condensed piperidines, e.g. piperocaine only substituted in position 2, e.g. methylphenidate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cardiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
ZA2011/09332A 2009-05-20 2011-12-19 Treatment of heart failure with normal ejection fraction ZA201109332B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/GB2009/050539 WO2010133815A1 (en) 2009-05-20 2009-05-20 Treatment of heart failure with normal ejection fraction

Publications (1)

Publication Number Publication Date
ZA201109332B true ZA201109332B (en) 2012-08-29

Family

ID=41213178

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA2011/09332A ZA201109332B (en) 2009-05-20 2011-12-19 Treatment of heart failure with normal ejection fraction

Country Status (11)

Country Link
US (3) US8440697B2 (enExample)
EP (1) EP2432470A1 (enExample)
JP (1) JP2012527438A (enExample)
CN (1) CN102573844A (enExample)
AU (1) AU2009346606B2 (enExample)
BR (1) BRPI0924398A2 (enExample)
CA (1) CA2816448A1 (enExample)
IL (1) IL216362A0 (enExample)
MX (1) MX2011012310A (enExample)
WO (1) WO2010133815A1 (enExample)
ZA (1) ZA201109332B (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0405381D0 (en) 2004-03-10 2004-04-21 Univ Wales Medicine A method and means for treating heart failure
WO2010133815A1 (en) 2009-05-20 2010-11-25 Heart Metabolics Limited Treatment of heart failure with normal ejection fraction
GB0908193D0 (en) 2009-05-13 2009-06-24 Albright Patents Treatment of disease state
US10137093B2 (en) 2011-08-16 2018-11-27 Cardiora Pty Ltd. Milrinone controlled-release formulation
WO2014036603A1 (en) * 2012-09-05 2014-03-13 Adelaide Research & Innovation Pty Ltd Uses of (-)-perhexiline
BR112017013015A2 (pt) * 2014-12-22 2018-03-06 Cardiora Pty Ltd método de tratamento de um paciente que possui falência cardíaca com fração de ejeção preservada (hfpef)
MX2019007125A (es) 2016-12-15 2019-09-16 Baxter Int Sistema y metodo para monitorizar y determinar parametros de paciente a partir de forma de onda venosa detectada.
US11039754B2 (en) 2018-05-14 2021-06-22 Baxter International Inc. System and method for monitoring and determining patient parameters from sensed venous waveform

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPN380695A0 (en) 1995-06-23 1995-07-20 Queen Elizabeth Hospital, The Methods related to the treatment of and isolation of compounds for treatment of ischaemic conditions
US20030162824A1 (en) 2001-11-12 2003-08-28 Krul Elaine S. Methods of treating or preventing a cardiovascular condition using a cyclooxygenase-1 inhibitor
CL2004000366A1 (es) 2003-02-26 2005-01-07 Pharmacia Corp Sa Organizada B USO DE UNA COMBINACION DE UN COMPUESTO DERIVADO DE PIRAZOL INHIBIDOR DE QUINASA p38, Y UN INHIBIDOR DE ACE PARA TRATAR DISFUNCION RENAL, ENFERMEDAD CARDIOVASCULAR Y VASCULAR, RETINOPATIA, NEUROPATIA, EDEMA, DISFUNCION ENDOTELIAL O INSULINOPATIA.
GB0405381D0 (en) 2004-03-10 2004-04-21 Univ Wales Medicine A method and means for treating heart failure
WO2005097121A1 (en) 2004-04-06 2005-10-20 Angiogenetics Sweden Ab Angiogenesis-affecting compounds and methods of use thereof
DE602006011363D1 (de) 2005-12-01 2010-02-04 Hoffmann La Roche Heteroaryl-substituierte piperidin-derivate als l-cpt1-hemmer
ITRM20060090A1 (it) 2006-02-22 2007-08-23 Sigma Tau Ind Farmaceuti Nuovi composti inibitori cpt a livello del snc come farmaci antidiabetici e o antiobesita
WO2010133815A1 (en) 2009-05-20 2010-11-25 Heart Metabolics Limited Treatment of heart failure with normal ejection fraction
GB0723100D0 (en) * 2007-11-23 2008-01-02 Heart Metabolics Ltd Treatment of HFnEF
GB0908193D0 (en) 2009-05-13 2009-06-24 Albright Patents Treatment of disease state
US20140019207A1 (en) 2012-07-11 2014-01-16 Sap Ag Interactive in-memory based sales forecasting
WO2014036603A1 (en) 2012-09-05 2014-03-13 Adelaide Research & Innovation Pty Ltd Uses of (-)-perhexiline
WO2015131231A1 (en) 2014-03-03 2015-09-11 Adelaide Research & Innovation Pty Ltd Methods for using (-)-perhexiline

Also Published As

Publication number Publication date
AU2009346606B2 (en) 2016-06-02
US8440697B2 (en) 2013-05-14
US20130210719A1 (en) 2013-08-15
JP2012527438A (ja) 2012-11-08
EP2432470A1 (en) 2012-03-28
CA2816448A1 (en) 2010-11-25
IL216362A0 (en) 2012-01-31
US9468634B2 (en) 2016-10-18
US20130210720A1 (en) 2013-08-15
US20100331364A1 (en) 2010-12-30
MX2011012310A (es) 2012-04-11
WO2010133815A1 (en) 2010-11-25
CN102573844A (zh) 2012-07-11
AU2009346606A1 (en) 2012-01-19
US9457017B2 (en) 2016-10-04
BRPI0924398A2 (pt) 2019-09-24

Similar Documents

Publication Publication Date Title
IL215975A (en) Heart failure device
EP2440209A4 (en) COMPOSITIONS AND METHODS FOR THE PREVENTION AND TREATMENT OF HEART FAILURE
GB0906642D0 (en) Cardiac pump
EP2408400A4 (en) RECONFIGURATION OF CARDIAC CHARACTERISTICS
EP2506888A4 (en) Total artificial heart
EP2478927A4 (en) CATHETER
IL216362A0 (en) Treatment of heart failure with normal ejection fraction
WO2010132347A9 (en) Docosahexaenoic acid for the treatment of heart failure
GB0908193D0 (en) Treatment of disease state
IL214133A0 (en) Skin treatment
IL212365A0 (en) Catheter structure
GB0906436D0 (en) Circulation Stimulator
GB2468946B (en) Suction catheter assemblies
GB0921060D0 (en) Catheter
GB0806047D0 (en) Treatment of heart failure
EG26793A (en) Medical injector
SI2323647T1 (sl) Dolgotrajno zdravljenje simptomatskega srčnega popuščanja
GB0908101D0 (en) Treatment of stress
GB0915319D0 (en) Combination medicament
GB201012099D0 (en) Catheter
EP2385855A4 (en) PROBE
HK1168551A (en) Treatment of heart failure with normal ejection fraction
ZA201005770B (en) The treatment of damaged skin
EP2496143A4 (en) HEART RATE MONITOR
GB0804320D0 (en) Treatment of heart failure